Short Title: OPTIMICE-PCR
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Study Number:
A012103
Study Status:
Enrolling
Treatment Agent:
Pembrolizumab
National Clinical Trial Identified Number: NCT05812807
Disease:
Study Phase:
III
researchcancer@cooperhealth.edu
De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Hide from Search:
Off
Physician Name:
Department:
Short Title: ARTEMIDE 03
The purpose of this study is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a 1L treatment for patients with non-squamous mNSCLC whose tumors express PD-L1 (TC ≥ 1%).
Study Number:
ARTEMIDE 03/D702FC00001
Study Status:
Enrolling
Treatment Agent:
Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
National Clinical Trial Identified Number: NCT06627647
Disease:
Study Phase:
III
researchcancer@cooperhealth.edu
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
Hide from Search:
Off
Physician Name:
Department:
Short Title: ARTEMIDE-02
The purpose of the study is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line (1L) treatment for patients with squamous metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 (tumor cells (TC) ≥ 1%).
Study Number:
ARTEMIDE-02/D702BC00001
Study Status:
Enrolling
Treatment Agent:
Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel
National Clinical Trial Identified Number: NCT06692738
Disease:
Study Phase:
III
researchcancer@cooperhealth.edu
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
Hide from Search:
Off
Physician Name:
Department:
